March 5, 2020 / 6:23 AM / in 25 days

BRIEF-Biocartis: New Immuno-Oncology Project With Bristol-Myers Squibb

March 5 (Reuters) - BIOCARTIS GROUP NV:

* BIOCARTIS ANNOUNCES NEW IMMUNO-ONCOLOGY PROJECT WITH BRISTOL-MYERS SQUIBB AIMED AT REGISTRATION OF IDYLLA™ MSI TEST IN CHINA

* BRISTOL-MYERS SQUIBB AND BIOCARTIS HAVE NOW AGREED TO ADD A NEW PROJECT UNDER THEIR COLLABORATION

* NEW PROJECT PURSUES REGISTRATION OF IDYLLA™ MSI TEST AS A CDX TEST IN MCRC IN PEOPLE’S REPUBLIC OF CHINA

* BIOCARTIS GROUP NV - BIOCARTIS’ JV WONDFO-CARTIS WILL COMMERCIALIZE IDYLLA MSI TEST IN CHINA UPON OBTAINING REGULATORY APPROVAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below